Listen

Checkpoint Well Taken: Identification and Management of Immune Related Adverse Events for Healthcare Practitioners

Patients taking immune checkpoint inhibitors (ICIs) are seen throughout all practice settings due to their impact on cancer survival and indications throughout many cancer types. ICIs have the potential to cause immune-related adverse events (irAEs), which can be a diagnostic and therapeutic challenge. This activity will discuss early identification and management irAEs to prevent progression leading to severe adverse effects and to avoid interruptions in life-prolonging ICI therapy. It is imperative that physicians, pharmacists, physician associates, nurse practitioners and nurses apply evidence-based guideline recommendations to patient-specific care plans to improve overall patient outcomes.

Monday, Dec. 8
11:30 a.m. - 1 p.m. PT (2:30 - 4 p.m. ET)

Symposium Location: Islander Ballroom G, Lower Level, Mandalay Bay North Convention Center

Come early! Seating is limited and provided on a first-come, first-served basis.

Can't make it to Las Vegas? Tune into the Free Live Webinar Broadcast.
Registration is required for the webinar.

Webinar Registration

Speakers

Jordan P. McPherson, PharmD, MS, BCOP, Activity Chair
Oncology Clinical Pharmacist, Huntsman Cancer Institute
Adjunct Assistant Professor, University of Utah College of Pharmacy
Salt Lake City, Utah

Jordan McPherson is Oncology Clinical Pharmacist in the ambulatory solid tumor clinics at the Huntsman Cancer Institute, an NCI designated cancer hospital, at the University of Utah Health and Adjunct Assistant Professor at the University of Utah College of Pharmacy in Salt Lake City, Utah. Dr. McPherson specializes in the treatment of skin cancer using immunotherapy and other targeted therapies. He serves as a Panelist on the NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities, and is Past President of the Utah Society of Health-System Pharmacists. Dr. McPherson’s research efforts are well published in peer reviewed journals, including the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, and Pharmacotherapy.

Pauline Funchain, MD
Associate Professor
Stanford University
Stanford, California

Dr. Funchain specializes in melanoma medical oncology, immunotherapy toxicities, and hereditary cancer genetics as an Associate Professor in the Division of Oncology at Stanford University. Dr. Funchain codirects the lmmunotherapy Toxicity (IOTOX) Working Group. She serves as the Associate Director for Cancer Research Training and Education (CRTEC) for the Stanford Cancer Institute as well as an Associate Program director for the Hematology/Oncology fellowship. Nationally, Dr. Funchain co-chairs the American Society of Clinical Oncology (ASCO) Guidelines Panel on Immune Related Adverse Events (irAEs). She co-founded and leads the Alliance for the Support and Prevention of Immune- Related Adverse Events (ASPirE).

Marianne Davies, DNP, ACNP, AOCNP, FAAN
Program Manager, Care Signature Pathway & Senior Oncology Nurse Practitioner, Yale New Haven Hospital
Associate Professor, Yale University-School of Nursing
New Haven, Connecticut

Dr. Davies has written and contributed to a number of scientific publications on immunotherapy and management of complications of cancer and cancer therapies. She has presented internationally on the management of irAEs at World Lung Cancer Conference, International Thoracic Oncology Nursing Forum, Society for Immunotherapy in Cancer, the Global Resource for Advancing Cancer Education (GRACE) lmmunotherapy Forum, ASCO-SITC Clinical Immuno-Oncology Symposium, ACCC-SITC Cancer Care Series and the Oncology Nursing Society. She is Chair of the ACI-SITC program development committee, a member of the NCCN Management of Immunotherapy-Related Toxicity Clinical Practice Guideline Panel, ASCO Immunotherapy Toxicity Guideline Panel and the SITC immune Checkpoint Inhibitor Survivorship Panel. She was inducted as a Fellow in the American Academy of Nursing (FAAN) in 2020.

Target Audience

This activity was planned to meet the educational needs of pharmacists, oncology and non-oncology physicians, physician associates, nurse practitioners and nurses who practice in hospitals, health systems, ambulatory clinics, and infusion centers who care for or are interested in the care of patients treated with immune checkpoint inhibitors.

Learning Objectives

Describe mechanisms of action of immune checkpoint inhibitors (ICIs) and how they relate to the pathophysiology of immune-related adverse events (irAEs).
Determine best methods to address potential ICI drug interactions based on current and emerging data.
Evaluate strategies for diagnosis and management of irAEs.
Develop interprofessional, evidence-based care plans for patients receiving ICIs who require irAE management taking into account patient-specific factors.

Agenda

11:30 a.m. - Welcome and Introductions
Jordan McPherson
11:35 a.m. - Background/Mechanism of Immune Checkpoint Inhibitors (ICIs), Comparison to other Treatment Toxicities
Jordan McPherson
11:45 a.m. - Current and Emerging Evidence Surrounding Drug Interactions of ICIs and their Influence on ICI Safety and Efficacy
Jordan McPherson
11:55 a.m. - Pathophysiology of Immune-related Adverse Events (irAEs) and General irAE Management Principles
Jordan McPherson
12:05 p.m. - Management of Common irAEs and Rare Serious irAEs
Pauline Funchain
12:35 p.m. - Patient Cases: Best Practices for Early irAE Identification/Management
All Faculty
12:45 p.m. - Faculty Discussion, Questions and Answers
All Faculty

Accredited for CPE

ACPE #: 0204-0000-25-410-L01-P
CE Credit: 1.5 contact hours (0.15 CEU)
Activity Type: Application-based
Activity Fee: No charge

To Claim CE for the webinar, enter the CE code announced during the activity and complete the evaluation.